POSITRIGO AG

Their core work

Positrigo is a Zurich-based deep-tech medical device company building compact, mobile brain PET (Positron Emission Tomography) scanners designed to make early Alzheimer's and dementia diagnosis accessible outside large hospital radiology departments. Their core innovation is shrinking and de-pricing brain imaging hardware that has historically required multi-million-euro installations, bringing it closer to point-of-care clinical settings. They progressed from a validated feasibility concept (BPET, 2019) to a full-scale commercial product development program (NeuroLF, 2020–2022), demonstrating a clear product-company trajectory rather than a pure research one. Their value to the healthcare system is direct: earlier detection of neurodegeneration at lower cost per scan, which matters enormously as Europe's aging population drives dementia caseloads upward.

What they specialise in

How they've shifted over time

Positrigo's H2020 participation spans only 2019–2022 and covers just two projects, so a long evolutionary arc is not visible. What is clear is a deliberate phase progression: BPET in 2019 was a minimal feasibility exercise with no recorded keywords — essentially a proof-of-concept to validate the market and technical approach. NeuroLF from 2020 onward carries a fully articulated keyword set (Alzheimer's, dementia, PET, brain scanning, diagnosis, ageing, cost-efficiency, healthcare), reflecting a shift from concept validation to structured product development with defined clinical and commercial targets. The trajectory is not a change in direction but a deepening of focus: the company entered the EU funding system knowing exactly what they wanted to build and used the SME instrument to fund successive stages of it.

Positrigo is on a product commercialization path — having secured Phase 2 SME funding, they are likely moving toward regulatory approval (CE/FDA) and clinical adoption, making them an interesting partner for hospital networks, diagnostics companies, and insurers rather than academic research consortia.

How they like to work

Positrigo has coordinated both of their EU projects independently, with no consortium partners recorded — consistent with the SME Instrument scheme design, which funds single companies rather than multi-partner consortia. This means they are experienced at driving a project from start to finish on their own terms, but have no documented track record of working within collaborative research networks. For a potential partner, this signals a self-directed, product-focused organization that will likely seek specific technical or clinical contributors rather than broad academic alliances.

Positrigo has no recorded consortium partners across their H2020 projects, as both were executed under the SME Instrument, which is a single-beneficiary scheme by design. Their collaborative network within EU-funded research is effectively uncharted from this data alone.

What sets them apart

Positrigo occupies a narrow but high-value niche: they are not building general-purpose medical scanners but a brain-dedicated, small-footprint PET system specifically calibrated for neurodegeneration diagnostics. This level of clinical specificity — combined with an explicit cost-efficiency mandate — positions them as a commercial technology provider rather than a research group, which is rare among EU-funded SMEs in medical imaging. For any consortium working on dementia care pathways, digital health for ageing populations, or accessible diagnostics, Positrigo brings a hardware product at an advanced development stage, not just IP or know-how.

Highlights from their portfolio

• NeuroLF
  The flagship project with €2.25M in EC funding represents one of the larger SME Phase 2 grants and is the vehicle for bringing Positrigo's brain PET scanner from prototype to market-ready product.
• BPET
  Though modest at €50k, this Phase 1 project is strategically notable as the validation step that unlocked the much larger NeuroLF grant, demonstrating a disciplined funding escalation approach.